Renowned Pharma and Biotech Development Leader, Dr. Andreas Wallnöfer, is named to Optigo Biotherapeutics’ Board of Directors as the company advances to IND-enabling studiesVANCOUVER, British Columbia, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Optigo Biotherapeutics (“Optigo”), an ophthalmology company pioneering next-gen treatments for retinal diseases, today announced that Dr. Andreas Wallnöfer is joining its Board of Directors as the company advances its lead program to IND-enabling studies.
Optigo Biotherapeutics Wins People’s Choice Award at Eyecelerator and Presents Compelling Preclinical Data on Long-Acting Intravitreal Biologics at the ARVO 2025 ConferenceVANCOUVER, British Columbia, May 06, 2025 (GLOBE NEWSWIRE) -- Optigo Biotherapeutics, a biotechnology company pioneering long-acting, bi-functional intravitreal biologics, today announced that it has been awarded the People’s Choice Award at Eyecelerator 2025 in Park City, Utah.
